Precision medicine, an established concept in the daily care of patients with cancer, has caused an increase in the number of biomarkers that need to be tested in the field of molecular pathology. 1 For example, RAS testing before antieepidermal growth factor receptor therapy is mandatory for patients with metastatic colorectal cancer. 2 The reliability and accuracy of biomarker testing is essential for optimal patient care, and errors might lead to the denial of treatment to a patient who could have benefited from it or to the overuse of these expensive therapeutic agents, which can even cause major adverse events. 3 The selection of the most optimal cell block, selection of the area for DNA extraction, and neoplastic cell content determination are critical steps in the molecular testing process to avoid false-negative results. Many laboratories have been using a nonenext-generation sequencing (NGS)-based commercial molecular method, 4 which requires a minimal amount of tumor DNA as validated by the kit manufacturer. This minimum amount of tumor DNA varies per testing method and can be translated to a minimum number of neoplastic cells. 5 In addition, laboratories that use a laboratory-developed kit need to validate their method and determine a minimal required number of neoplastic cells. Accurate estimation is especially important for testing with NGS, because tumor cellularity is essential to distinguish between signals and noise. 6 Moreover, an accurate neoplastic cell content estimation helps to set a minimal read depth, because samples with low cellularities require higher coverages. 7, 8 There is no gold standard to determine the percentage of neoplastic cells. 9 Pathologists are often trained to estimate the neoplastic cell content by looking at a hematoxylin and eosin (H&E)estained formalin-fixed, paraffin-embedded tissue slide. Previous studies already indicated that this estimation by pathologists is prone to interobserver variation. 10e13 This variation is especially critical for samples with a low number of neoplastic cells, because overestimations might lead to false-negative results. 14e16 It is uncertain which estimation strategies for the neoplastic cell content are used in Europe and how the area in the tissue to be used for DNA extraction is indicated. Although previous studies have identified variation in the estimations, no largescale data are available about the selection of the tumor zone in a sample or the estimations. 8e11 Therefore, this study aimed to gain insight in the current practices in Europe and to identify factors that impact the way the tumor is delineated and the neoplastic cell content estimated.
Materials and Methods

Study Context
Insight in current practices of estimating the neoplastic cell content was gained based on data from the external quality assessment (EQA) program for metastatic colorectal cancer between 2011 and 2017. This is an annual program organized by the European Society of Pathology (ESP) Quality Assurance Foundation (Brussels, Belgium). Participating laboratories in the EQA scheme received 30 pretested, blank, formalin-fixed, paraffin-embedded tissue slides originating from 10 different samples for analysis with their routine protocols. After analysis, laboratories were asked to submit the following: genotyping results, a questionnaire about their laboratory characteristics and testing strategy, diagnostic reports for three cases based on mock clinical information, and scans of the H&E-stained slides on which the area selected for DNA extraction was delineated and the neoplastic cell content was estimated. Two independent assessors (J.H.v.K. and G.D.H.), who are experts in molecular pathology of metastatic colorectal cancer, assessed the results.
Study Design
This study consisted of three parts. In the first part, the methods for determining the neoplastic cell content were retrieved from the questionnaires that were part of the ESP Colon EQA schemes between 2011 and 2017, and these data were supplemented by an additional questionnaire with more specific questions regarding the individual who estimated the cellularity, the estimation protocol, integration with micro-and/or macrodissection, and post-analytical use in 2017 (Supplemental Appendix S1). The second part of the study covered variation in cellularity estimations and how the zone for DNA extraction was delineated; therefore, general questionnaires of the ESP Colon EQA schemes and images scanned by the laboratory of H&E slides on which the area for DNA extraction was delineated from 2011 to 2017 were used. In the third part, information regarding ways of reporting the neoplastic cell content was retrieved from the questionnaire of the ESP Colon EQA schemes of 2016 and 2017, and uploaded pathology reports. Questionnaires were designed using FormDesk software version 4.0.14 (Innovero Software Solutions B.V., Wassenaar, the Netherlands) and provided to the participants via their private account on the website (EQA, http://kras.eqascheme. org, last accessed January 27, 2018). Nonrespondents received e-mail reminders 14 and 30 days after the initial invitation. Table 1 gives an overview of the number of samples that was sent between 2011 and 2017, the number of participants that gave their estimations, and the number of scheme organizers. Due to the large number of participants, different scheme organizers distributed samples during the schemes of 2011 to 2016. 4, 17 Variation in neoplastic cell estimations was calculated in two ways: based on the average estimation for each sample and based on a consensus value. Consensus was reached after independent determination by two pathologists with more than 10 years of experience in molecular pathology. In addition, laboratories uploaded scans of the H&E-stained slide on which the area for DNA extraction was delineated. Delineations were categorized in six categories ( Figure 1 ). Small circles and small squares were chosen when the diagonal diameter of the area was smaller than 5 mm. Precise tumor shape was chosen when the zone was indicated with dots. For statistical analysis, delineations were also bundled into gross methods (gross tumor shape, gross square, gross circle), precise methods (precise tumor shape, small circle, small square), and whole tumor section. Error rates were calculated as the ratio of the number of participants that made a genotyping or technical error and the total number of participants. Genotyping errors consisted of reporting a falsepositive or false-negative result or a wrong mutation, and examples of technical errors were problems with DNA extraction, library preparation, probe hybridization, and so on.
Data Analysis
Statistical Methodology
Statistical analysis was performed with c 2 tests for comparison of categorical variables, paired t-tests for continuous variables, and one-way analysis of variance followed by Tukey honest significant difference analysis for a mixture of continuous and categorical variables. P 0.05 was considered significant. Bonferroni corrections were applied when necessary. All statistical analyses were performed using R Software version 3.4.0 (The R Foundation for Statistical Computing, Vienna, Austria).
Results
Variability in Estimation Processes of Neoplastic Cell Content Exists
In the first part of the study, the methods for determining the neoplastic cell content were analyzed. Figure 2A shows which individuals were involved in the determination of the neoplastic cell content in daily practice. In the majority of laboratories, this was the pathologist, but in some laboratories, technicians or molecular biologists were doing the primary determination with subsequent confirmation by a pathologist. It was also of interest whether one group performed better than the others. No significant differences in error rates for genotyping (P > 0.05; 95% CI, À0.20 to 0.15) were observed between determination by the pathologist alone and determination by the molecular biologist or technician followed by confirmation by the pathologist. There were only three participating laboratories where technicians or molecular biologists performed the estimation without confirmation by a pathologist. For improving reader friendliness of this article, the pathologist refers to the individual who estimates the neoplastic cell content.
Survey results of 43 of 102 laboratories (42%) gave more detailed information on how the content of neoplastic cells was determined in daily practice in 2017 ( Figure 2B ). The largest group of pathologists (40%) determined the neoplastic cell content as the ratio of neoplastic cells to all cells in a tumor-rich area selected for DNA extraction. Only 9% used their specific protocol for the determination (eg, detailed description of the magnifications used for defining the area with most viable neoplastic cells and the estimation). Manually counting cells in a limited number of areas was done in three laboratories.
There was variation, not only in the methods for estimating the neoplastic cell content, but also in the way tumor zones were delineated ( Table 2) . Pathologists who estimated the neoplastic cell content in a selected area also indicated which factors were taken into account for annotating that area. Factors that were considered important were infiltration by immune cells (n Z 37; 86%), spread of neoplastic cells (n Z 33; 77%), desmoplastic stroma (n Z 30; 70%), necrosis (n Z 29; 67%), mucus (n Z 23; 53%), and fat (n Z 2; 5%). Spread of neoplastic cells means the presence of clusters of a few neoplastic cells spread over the tissue slide.
To define the current state of the art, this study also covered tumor enrichment methodologies used in 2017. Three laboratories (7%) did not perform any form of dissection, and these three laboratories made no error during the ESP Colon Scheme of 2017. These laboratories used three different testing methods: a noneNGS-based commercial kit (KRAS/BRAF Mutation Analysis Panel Kit; EntroGen, Woodland Hills, CA), an NGS-based commercial kit (TruSight Tumor 15; Illumina, San Diego, CA), and a noneNGS-based laboratory-developed technique (LDT; dideoxy sequencing). The other laboratories performed macrodissection (n Z 32; 74%), microdissection (n Z 2; 5%), or both (n Z 6; 14%). There were as many laboratories taking tissue directly from the tissue block as from the tissue slide. When tissue was taken from a slide, most laboratories (58%) used dry scraping. Others used wet scraping (32%) or laser-guided microdissection (11%). 
Several Factors Influence Variation in Neoplastic Cell Content and Delineation of the Tumor Zone
Results on the extent of the variation of neoplastic cell content estimations between pathologists showed that the differences between the highest and the lowest estimations were between 52% and 78% ( Figure 3 ). The average deviation from the sample mean and consensus lay between 12% and 23%. More underestimations (estimation of at least 20% lower than the average value) than overestimations (estimation of at least 20% greater than the average value) were made ( Table 3) . For samples with a consensus value around the diagnostic threshold of most testing methods ( 30% of neoplastic cells), 5 the percentage of overestimations was 58%, on average ( Figure 4 ).
It was also studied which factors might influence neoplastic cell content estimations and how pathologists delineate the tumor-rich zone ( Table 4) . No correlation was seen between the neoplastic cell content estimation and the slide rank, which is an indicator for the place in the block where the tissue slide was taken. Pathologists who used precise delineation methods (small circle, small square, or precise tumor shape) made higher estimations than pathologists who use gross delineation methods (gross circle, gross square, gross tumor shape, and whole tumor section). Laboratory accreditation did not have an impact on the estimation, but influenced the way the tumor zone is delineated, because pathologists in nonaccredited laboratories were using more gross delineation methods (gross tumor shape, gross square, and gross circle) and whole tumor sections. Estimations and delineations also differed among European regions ( Supplemental Table S1 ). In the southern and southeastern parts of Europe, higher estimations were made and more precise delineations of the tumor zone were given ( Figure 5 ). The use of noneNGSbased LDTs was correlated with higher estimations as compared with noneNGS-based commercial kits and NGS. In addition, noneNGS-based LDT methods were related to lower method sensitivities than noneNGS-based commercial kits and NGS (P < 0.0001). Consequently, there was a negative correlation between the sensitivity of the analysis method and the neoplastic cell content estimation. Laboratories that used a method that required a high percentage of neoplastic cells also used more precise ways to delineate the tumor zone. For NGS, a further distinction was made between commercial and laboratory-developed NGS techniques. The same principles as for noneNGS-based commercial kits and noneNGS-based LDTs applied. In 2017, estimations from laboratories that use laboratory-developed NGS techniques were higher (P < 0.001) and delineations were more precise (P < 0.0001) than laboratories that use commercial NGS techniques. For the other years, statistical evidence could only be obtained for the correlation between the delineation method and the NGS technique, although the same trends were observed for the relation with the estimations.
Making genotyping errors was correlated with higher estimations, but not with the delineation method, except for 2013 and 2014 to 2015. In those years, genotyping errors were correlated with using gross delineation methods and/or 
Pitfalls in the Interpretation of Neoplastic Cell Content
The third part of the study covered the interpretation of the neoplastic cell content. In 2017, 93 of 102 laboratories (91%) where the neoplastic cell content was estimated in routine included the neoplastic cell content in their test report, but only 49 (53%) took it into account for result interpretation. Of the laboratories that used a noneNGSbased commercial kit (n Z 51), 75% included the percentage in the report, and 41% took it into account for interpretation. For the NGS users (n Z 28), these rates were 82% and 57%, respectively, and for the users of a noneNGS-based LDT (n Z 23), they were 96% and 57%, respectively. During the ESP Colon EQA schemes of 2016 and 2017, a sample without neoplastic cells was distributed. Of a total of 123 and 105 participants in 2016 and 2017, respectively, 10 laboratories in 2016 and 21 in 2017 did not take the absence of neoplastic cells into account and genotyped the sample wrongly as wild type. Others (8 in 2016; 12 in 2017) mentioned the zero neoplastic cells in their report but interpreted this wrongly, for example by recommending therapy after analysis (6 in 2016; 11 in 2017) or even without analysis (1 in 2017), or by stating that the sample was suitable for analysis (2 in 2016). There were also laboratories that incorrectly claimed that the sample contained neoplastic cells (11 in 2016 and 2 in 2017). Of those 13 laboratories, 7 laboratories reported that the sample was suitable for analysis and recommended therapy, 5 laboratories added a note that the result should be interpreted with care due to the low neoplastic cell content, and 1 laboratory did not submit written reports.
Six out of seven laboratories that participated both in 2016 and 2017 and genotyped the sample wrongly as a wild type in 2016 did not make the same mistake in 2017. Five of six laboratories no longer interpreted zero neoplastic cells incorrectly in 2017, and no laboratory twice found neoplastic cells in a sample without them.
Discussion
Neoplastic cell content determination before biomarker testing is crucial to obtain accurate test results. When the true neoplastic cell content is around the threshold of the test method, the result might become dubious because signals from nontumor DNA dilute signals from tumor DNA. Overestimations might thus lead to false-negative results and might keep the patient from receiving the correct therapy. Underestimations, on the other hand, are considered as less severe, although they might cause retesting and require an unnecessary search for new samples. Newer testing techniques, such as NGS, might work with a lower number of neoplastic cells. Although a reliable estimation might become redundant in the high range of neoplastic cell content for this technique, it becomes more critical in the lower ranges. Furthermore, it is still needed to correctly interpret the ratio of mutated versus nonmutated alleles. In this study, current practices used for the determination of neoplastic cell content were analyzed, variances in the estimations and in the way areas for micro-or macrodissection were indicated were evaluated, and in addition, problems with interpretation of samples without neoplastic cells were identified.
Variability in Estimation Processes of Neoplastic Cell Content Exists
In a small number of laboratories, nonmedical technicians or medical biologists are determining the neoplastic cell content with or without pathologist supervision (Figure 2A ). In the future, an increase in this phenomenon is expected to make the testing process more time-and cost-efficient, and to anticipate a shortage of pathologists. 18e21 Training will be crucial to prevent that technicians or molecular biologists become only experts in recognizing patterns without using clinical and morphological information. 19 Also, during molecular tumor boards, morphological information from the tumor might be necessary. A large group of pathologists have not specified whether they estimated the neoplastic cell content in a tumor-rich area or in the whole tumor section. This problem was also elaborated by a French study by Lhermitte et al 11 that states that the lack of a good definition for neoplastic cell content causes variability. Although exact counting of cells (manually or machineassisted) might give the most accurate result, this was only done in three laboratories. The study by Lhermitte et al 11 also identified lymphocytic infiltration and extracellular mucin as factors that impact the estimation. Our study confirmed these factors and identified several others such as the spreading of neoplastic cells, desmoplastic stroma, and necrosis.
The materials and methods sections of studies often state that dissection was performed to enrich for tumor content. 15, 22 In this study, 7% of the laboratories never performed any form of dissection. Because testing strategies designed for whole tumor sections are not available yet, this could be poor practice. For noneNGS-based commercial kits, tissue was mostly taken from the block, whereas for noneNGS-based LDTs and NGS, tissue slides were taken. The reasons for this difference are unclear, and no statistical differences in neoplastic cell content estimations and delineation methods were observed. Taking tissue from an unstained slide might be preferred because it avoids permanent damage to the tumor block. Although multiple options exist for taking tissue directly from the tissue block (eg, punching cylinders out the block or cutting by knife), this was not further addressed in our study.
Several Factors Influence Variation in Neoplastic Cell Content and Delineation of the Tumor Zone
In addition to analyzing current practices, this study aimed to quantify the variation between different estimations (Figure 3 ). Several studies have done this before, however, not on a large-scale or longitudinally. 11e13 In this study, the average difference between the highest and lowest estimation lies between 52% and 78% between 2011 and 2017 (N Z 5776), which matches the 64% of the AFAQAP survey This study now confirms on a larger and country-wide scale the findings of Lhermitte et al 11 and Smits et al 12 who also demonstrated that more underestimations than overestimations are made. Nevertheless, overestimations are especially dangerous around the diagnostic threshold of a test method. 10 The percentage of overestimations for samples containing a low neoplastic cell content ( 30%, according to the consensus value) was alarmingly high for several of those samples (eg, 92% of 13 for a sample from 2014), stressing the need for standardization ( Figure 4) .
Several factors were significantly correlated with neoplastic cell content estimations and the way the tumor-rich zone used for dissection is delineated ( Table 3 ). Pathologists that use precise delineation methods have higher estimations than those using gross methods. This is logical because by precisely indicating the tumor, non-neoplastic cells that contaminate the sample are excluded. Methods for mutation detection can also impact neoplastic cell content estimations and tumor delineations because they have different workflows and require different minimal amounts of neoplastic cells for a reliable result. 5 Traditional noneNGS-based LDTs require a higher percentage of minimal neoplastic cells than non-NGS commercial kits and NGS. This clarifies the correlation between the use of noneNGS-based LDTs and a more precise delineation method, on the one hand, and a higher neoplastic cell estimation, on the other hand.
Pathologists thus seem to be aware of the fact that the zone for dissection should be as pure as possible for methods with lower sensitivity, such as noneNGS-based LDTs. Variation was also observed between different parts of Europe. At the moment, reasons for these differences are unclear and could be further studied.
It was also studied whether estimations and delineations were correlated with the number of genotyping errors and technical failures (Table 3 ). Overall, laboratories that made a genotyping error reported higher neoplastic cell contents and were more likely to use gross estimation methods or whole tumor sections. The combination of overestimating the neoplastic cell content and using a gross estimation method could thus indeed be dangerous for obtaining false-negative results, as was already hypothesized by several studies. 11e13 In this study, it was not taken into account whether laboratories made only one or more than one genotyping error, because a laboratory that made a genotyping error during an EQA scheme is probably also at risk for making errors during routine analysis. For technical failures, two tendencies were observed: using whole tumor sections on the one hand and using small circles on the other hand. When whole tumor sections are used, the minimal required percentage of neoplastic cells is probably not met, and tissue heterogeneity might be higher than in dissected slides. 23 By contrast, using small samples might lead to technical failures because many methods also require a minimal absolute number of neoplastic cells.
Pitfalls in the Interpretation of Neoplastic Cell Content
Several guidelines and checklists (eg, cancer protocols and checklists from the College of American Pathologists, available at http://www.cap.org/web/home/protocols-andguidelines/cancer-reporting-tools/cancer-protocol-templates, last accessed December 15, 2017) state that the neoplastic cell content should be included in the test report. 24, 25 Most laboratories in this study are doing this; however, this information is not always taken into account when interpreting the test result. These findings were also previously confirmed by a study by Tembuyser et al 17 in which a sample with a borderline neoplastic cell content led to a higher rate of false-negative results. The fact that many laboratories do not use the neoplastic cell content when interpreting test results could affect patient outcome. Although clinicians who read the reports usually have basic knowledge about testing techniques, it is uncertain whether they know what to do with this information without a clear interpretation. And even when the neoplastic cell content is interpreted, this is not always done correctly as was demonstrated by the samples without any neoplastic cells. These results stress the need for training pathologists and residents in the field of molecular pathology. Molecular analysis in a sample without neoplastic cells is a waste of time and money, and incorrectly reporting wild-type results could harm the patient. It is very concerning that in (Table 3) . EQA, external quality assessment; ESP, European Society of Pathology; NC%, percentage neoplastic cells. jmd.amjpathol.org -The Journal of Molecular Diagnostics 2016, 10% of the pathologists identified non-neoplastic cells as neoplastic cells. This might indicate a certain unawareness of the importance of the determination of the neoplastic cell content. These data also show that the majority of laboratories that made an interpretation error in 2016 did not make the same mistake in 2017. A learning process is thus already triggered and stresses the need for continued education and participation in EQA schemes.
Next Steps
In this study, digital tools to estimate the neoplastic cell content were not used by any of the participating laboratories. At the moment, a limited number of systems are commercially available for in vitro diagnostic use in Europe. 26, 27 If these digital tools are thoroughly validated and trained to recognize neoplastic cells, they might be a solution for interobserver variation. Therefore, further comparisons between visual and digital estimations should be made. On the other hand, laboratories will not immediately make the switch to digital estimations. It is thus important that sufficient attention is paid to the determination of the neoplastic cell content and additional training is needed, for the delineation of the tumor area and the neoplastic cell content estimation, but also for reporting and interpreting. Because molecular testing is becoming organized in a more centralized way, 28 selection of the most suitable block for molecular analysis and a clear report will become even more important. Also in case of centralization, pathologists have a duty to check the sample selected for molecular analysis on H&E for neoplastic cell content, because they cannot be certain who selected the sample and if there was a review before shipment to the central laboratory. The authors have already initiated a project to develop a best-practice guideline. Ten experts from 10 different countries were invited to obtain consensus on the following topics; the individual who should perform the morphological evaluation of the sample and who should determine the neoplastic cell content, selection of the most viable tumor area, assessment of the homogeneity of the sample, practices for macrodissection, necessary control steps, and requirements for reporting.
Conclusions
An accurate estimation of the neoplastic cell content is essential for reliable biomarker testing. Variation in the different practices for the indication of the zone for microor macrodissection and the estimation of the neoplastic cell content in that zone exists. Moreover, variation in tumor zone delineations and cellularity estimations between different pathologists was quantified. In addition, a high number of overestimations in samples containing a neoplastic cell content around the threshold of the test methods was observed. The post-analytical use of neoplastic cell content information should also be improved, since reporting false negative results could affect patients. Standardization of practices is thus necessary for assuring that the minimal percentage of neoplastic cells that is required for testing methods is met and for correctly interpreting the results. This process could be assisted by conceiving and distributing a best practice guideline.
